Total Funding
61
46
Total FundingGrant raised
Growth Score
-1 pts
Heat Score
-3 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
57883
SonALAsense develops SDT (Sonodynamic Therapy) intended to turn glioblastoma multiforme (GBM) patients into cancer survivors.
- Stuart Marcus: Founder, CEO & CMO
- Mark De Souza: President and CEOPast Role: Willow Neuroscience, Co-Founder, President and CEO
About the Company
SonALAsense develops SDT (Sonodynamic Therapy) intended to turn glioblastoma multiforme (GBM) patients into cancer survivors. It utilizes MRI-guided focused ultrasound (the device) in combination with aminolevulinic acid (a drug) to selectively target and kill tumor cells. Their use of an MRI-guided focused ultrasound device with ALA is a true
drug-device combination, where both the drug and the device are required for a therapeutic effect. SDT has a well-elucidated mechanism of action (creation of reactive oxygen species).
The company was founded in 2019 and is based in Berkeley, California.
